Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2008 new-tech add-on payments

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific's Wingspan intracranial stent with Gateway balloon catheter is the only applicant for an inpatient new technology add-on payment in fiscal 2008 after CMS extended the deadline until Dec. 30, 2006, to allow time for more submissions (1"The Gray Sheet" Nov. 27, 2006, p. 14). Boston Scientific applied for a new-tech add-on for the device in fiscal 2006, but the bonus payment was denied because WingSpan was not FDA-approved at the time of the decision. WingSpan gained a humanitarian device exemption from FDA in August 2005. CMS maintained longstanding noncoverage for the device, except when used in FDA trials, in a November 2006 coverage decision, but may soon expand coverage to other research settings (2"The Gray Sheet" Dec. 18, 2006, p. 6). A "town hall" meeting to discuss the lone applicant is scheduled for Feb. 22 in Baltimore...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel